5 Names Trending Now (Open for names)

Tickers Inside Dear Reader, According to our research, there are a few trending companies that have recently received buy ratings and showing a combination of positive investor sentiment, news headlines and blog buzz. With that said, we are not recommending buying these names but we are adding them to our stock watchlist. We will continue to monitor companies to see if the momentum continues. --------------------------------------------------------------- Sponsor [Nobel Prize Winner's Premonition About Nuclear Energy Comes True]( [Will This Nuclear Revival Send Uranium On a New Bull Run?]( --------------------------------------------------------------- [TG Therapeutics In., TGTX]( Summary: TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York. Joshua Schimmer analyst at Evercore ISI reiterates coverage on [TG Therapeutics In. (TGTX)]( with a Buy rating and has set a price target of $ 16. [TipRanks.com]( reports that [TG Therapeutics In.]( has 8 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $19.75. In addition, TradingView issued a Strong Buy rating for [TGTX]( over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. [For the chart and additional details on TGTX, please click here >>]( [Tesla, TSLA]( Summary: Tesla is the market leader in battery-powered electric car sales in the United States, with roughly 70% market share. The company's flagship Model 3 is the best-selling EV model in the United States. Tesla, which has managed to garner the reputation of a gold standard over the years, is now a far bigger entity that what it started off since its IPO in 2010, with its market cap crossing $1 trillion for the first time in October 2021.' The EV king's market capitalization is more than the combined value of legacy automakers including Toyota, Volkswagen, Daimler, General Motors and Ford.Over the years, Tesla has shifted from developing niche products for affluent buyers to making more affordable EVs for the masses. The firm's three-pronged business model approach of direct sales, servicing, and charging its EVs sets it apart from other carmakers. Tesla, which is touted as the clean energy revolutionary automaker, is much more than just a car manufacturer. Alexander Potter analyst at Piper Sandler reiterates coverage on [Tesla (TSLA)]( with a Buy rating and has set a price target of n/a. [TipRanks.com]( reports that [Tesla]( has 31 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $264.27. In addition, TradingView issued a Sell rating for [TSLA]( over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Neutral short-term outlook. [For the chart and additional details on TSLA, please click here >>]( --------------------------------------------------------------- Sponsor [New Documentary From Porter Stansberry: The Two Men Destroying America]( Inside the secret plan to decimate the savings, investments, and way of life for millions of unsuspecting Americans... [Click play to stream the documentary for free.]( --------------------------------------------------------------- [Ardelyx, ARDX]( Summary: Ardelyx, Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and commercializes small molecule therapeutics that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases. The Company's lead product candidate is Tenapanor which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. Ardelyx, Inc. is headquartered in Fremont, California. Christopher Raymond analyst at Piper Sandler reiterates coverage on [Ardelyx (ARDX)]( with a Buy rating and has set a price target of $ 8. [TipRanks.com]( reports that [Ardelyx]( has 5 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $5.00. In addition, TradingView issued a Strong Buy rating for [ARDX]( over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. [For the chart and additional details on ARDX, please click here >>]( [MAG Silver, MAG]( Summary: MAG Silver is a Vancouver-based advanced stage exploration and development company that is focused on the acquisition, exploration and development of high-grade, district-scale projects located primarily in the Americas. The Company's principal asset is a 44% interest in the Juanicipio joint venture located in Mexico, which is now in the construction phase heading to production. The Company also owns a 100% interest in the Cinco de Mayo Project, also located in Mexico. Don DeMarco analyst at National Bank reiterates coverage on [MAG Silver (MAG)]( with a Buy rating and has set a price target of $ 18.08. [TipRanks.com]( reports that [MAG Silver]( has 9 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $17.88. In addition, TradingView issued a n/a (possibly response change) rating for [MAG]( over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Neutral short-term outlook. [For the chart and additional details on MAG, please click here >>]( --------------------------------------------------------------- Sponsor [More, More, More & Nuclear Energy, That Is...]( "perfect storm" of factors is breathing new life into the nuclear energy sector. The U.S. is working hard to build more advanced nuclear plants to achieve clean energy and climate goals. However, America's reliance on Russia for uranium has grave implications for national security. Fortunately, billions of dollars in Govt. incentives are now up for grabs to help revive the domestic uranium industry. [See How Investors Could Benefit From the Nuclear "Renaissance"]( --------------------------------------------------------------- [PDS Biotechnology, PDS]( Summary: Precision Drilling Corporation is an oilfield services company. The Company provides contract drilling, well servicing and strategic support services to the oil and gas industry in North America and internationally. It provides land drilling, directional drilling, turnkey drilling, camp and catering services, procures and distributes oilfield supplies. It also offers service rigs for well completion and workover services, snubbing services and wastewater treatment services, tubulars, well control equipment, wellsite accommodations. Precision Drilling Corporation is headquartered in Calgary, Canada. [Andrew Bradford analyst at Raymond James reiterates coverage on]( Biotechnology (PDS)]( with a Buy rating and has set a price target of $ 103.32. [TipRanks.com]( reports that [PDS Biotechnology]( has 8 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $98.73. In addition, TradingView issued a Buy rating for [PDS]( over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bullish short-term outlook. [For the chart and additional details on PDS, please click here >>]( --------------------------------------------------------------- Sponsor [Banking Regulators Warns Americans to Pay Attention to Friday, December 30th]( [Get the Full Story Here]( --------------------------------------------------------------- Remember, securities are volatile, so please do your own research. One resource you need to consider using [Tipranks.com]( where as a premium member you get access to all buy ratings, price targets and insider trading signals. [Get more from TipRanks.com here >>]( Thanks for reading! The Editor, [wallstreetanalystpress.com]( --------------------------------------------------------------- Sponsor Friends… On October 27, the CEO of New England’s largest energy company sent a desperate letter to the White House. ["This represents a serious public health and safety threat,"]( CEO Joe Nolan wrote in a letter to President Joe Biden. He then begged Joe Biden to use the federal government's emergency powers to make sure natural gas will be available in New England this winter. There’s only one problem. There’s nothing Biden or anyone can do at this point. All available natural gas is on its way to Europe. When large parts of New England go dark and freeze this winter, a lot of people will call it a shocking natural disaster. Or they’ll say it was because Russia invaded Ukraine. But cities don’t go dark and freeze in the wealthiest country in the world by accident. My name is Porter Stansberry. I’m the founder of one of the world’s largest financial research firms. I’ve spent the last two years researching this coming crisis. I’ve been writing about it in my newsletter, The Big Secret on Wall Street, since June… And now that this crisis is set to unfold, exactly the way I’ve been predicting, I’ve uploaded an eye-opening video that tells the whole sordid tale. I name names in it. And I reveal who caused this crisis, and why… Do yourself a favor. Before it’s taken offline – which could happen at any time – check out this [shocking video](. I’ve seen in the past just how far powerful people will go to silence me. Don’t miss this: [CLICK HERE.]( --------------------------------------------------------------- [To Cancel Your Free Subscription, click here.]( WallStreetAnalystPress.com Press Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. Content marked as "Ad," "Special" or "Sponsor" may be a third party advertisements where the advertiser is paying per click, per lead or per sale and are not endorsed or warranted by our staff or company. Sandpiper Marketing Group, LLC is also being compensated by Summit Publishing Group and Investing Trends up to three dollars per click and may exceed twelve thousand, five hundred dollars per week for placement of specific advertisements contained in this newsletter. Sandpiper Marketing Group, LLC and its principles do not own any of the stocks mentioned in this email or in the article that this email links to. Please see the disclaimer on the advertiser's website for additional information, including their relationship with any mentioned security. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. This newsletter may contain information regarding investment ideas and third-party ratings regarding specific securities. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. Sandpiper Marketing Group, LLC nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from Sandpiper Marketing Group, LLC to buy or sell any security. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. By opening this email or clicking any links contained, you are reconfirming your opt-in status. You can unsubscribe at any time by clicking the link below in the footer. This is part of your free subscription to WallStreetAnalystPress. WallStreetAnalystPress.com part of Sandpiper Marketing Group, LLC | 1519 Mecklenburg Hwy Unit 407 | Mt. Mourne | North Carolina | 28123 [UNSUBSCRIBE](